"Can we infer any impact on MSB-MNK deal from the MNK bid to acquire sucampo?"
@valueinvesting,
Good question.
Judging from Sucampo's quite healthy financials (Revenue of ~US$250m and EBITDA of ~$125m), it looks like MNK is acquiring an earnings stream (presumably to fill MNK's earnings hole which has been widening over the past 12 months).
Ann: Mesoblast Receives RMAT For LVAD Heart Failure Patients, page-107
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |